Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 20/20 | 0.67 |
| ▸ | CRBN | Q96SW2 | 20/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.67 |
| ▸ | TNF | P01375 | 1/20 | 0.67 |
| ▸ | IL1B | P01584 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355751 | 0.92 | CRBN (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL283120 | 0.91 | CRBN (0.68) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18509378 | 0.89 | CRBN (0.66) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL328520 | 0.89 | CRBN (0.66) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19526118 | 0.88 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL282837 | 0.88 | CRBN (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18900417 | 0.88 | CRBN (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26320556 | 0.88 | CRBN (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL31316579 | 0.88 | CRBN (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL282858 | 0.87 | CRBN (0.62) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11040925-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190330124-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-10202316-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170158579-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, IL15, CXCR5 | DDB1 781/4885CRBN 2228/4885IKZF3 14/4885 |
| US-11040925-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, TLR5, IDO1 | DDB1 1162/4885CRBN 1871/4885IKZF3 9/4885 |
| US-20190330124-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | DDB1 1162/4885CRBN 1871/4885IKZF3 9/4885 |
| US-20170158579-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | DDB1 1162/4885CRBN 1871/4885IKZF3 9/4885 |
| US-10202316-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, TLR5, IDO1 | DDB1 1162/4885CRBN 1871/4885IKZF3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.